Halozyme Trims Workforce

Xconomy San Diego — 

Halozyme Therapeutics (NASDAQ: HALO) said it plans to decrease research relating to the discovery and preclinical assessment of new compounds in a strategic refocusing that will require laying off about 30 workers, or 25 percent of the company’s workforce. Halozyme said it is focusing its resources on developing and commercializing three compounds already in clinical trials—a rapid-acting insulin product for treating diabetes, and two enzyme compounds.